0674 The Functional Impacts of Narcolepsy Instrument Differentiates Patients with Narcolepsy from Healthy Controls

Stephen Crawford,Heather Romero,Yulia Savva,Peter McPherson,Helen Doll,Amy Howerter,Todd Swick

DOI: https://doi.org/10.1093/sleep/zsae067.0674

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction The Functional Impacts of Narcolepsy Instrument (FINI) is a fit-for-purpose patient-reported outcome (PRO) measure developed for the assessment of patients with narcolepsy type 1 (NT1) or type 2 (NT2). To provide a baseline for interpretation in future interventional trials, comparative scores for the FINI domains were obtained from a cohort of healthy volunteers included in a United States observational study. Methods Healthy volunteers without excessive daytime sleepiness (EDS; ≤10 on the Epworth Sleepiness Scale [ESS] at screening) or any associated medical disorder were eligible for inclusion. Participants received a link to complete a cross-sectional online survey that included a 23-item, 5-domain form of the FINI (excluding cataplexy items) and additional selected quality of life reference questionnaires (SF-36 and EQ-5D). FINI items evaluate narcolepsy/EDS symptoms and impacts on daily functioning. All items have a 7-day recall period on a 5-point Likert scale of frequency from “never” to “always” or severity from “not at all” to “very much.” For each domain, an average item score is calculated and standardized to a 0–100 scale. Lower scores indicate better health/functioning. Responses were compared to patients with NT1 and NT2 from an observational study (n=126) and a phase 2 trial (NCT04096560; n=125). Results Thirty-one healthy volunteers (45.2% female) completed the survey. Participants had a mean age of 44.8 years and a median (range) ESS score of 4.0 (0–10.0) at baseline. FINI domain scores ranged from 10.0 to 22.2 in healthy volunteers, significantly lower than values reported for patients with narcolepsy in observational and phase 2 studies (46.2 to 67.9). Similar patterns were observed for reference PROs, with better quality of life/health status reported for healthy controls than for narcolepsy samples. Mean (SD) FINI domain values for healthy volunteers were: Tiredness: 22.2 (19.8); Cognitive Functioning: 10.0 (10.5); Social Activities: 16.1 (17.1); Everyday Activities: 12.9 (10.7); and Everyday Responsibilities: 11.6 (15.8). Conclusion Mean FINI domain scores from healthy volunteers can serve as normative thresholds and provide a benchmark for comparison of FINI responses reported by patients with narcolepsy, allowing for the evaluation of treatment effects in clinical trials. Support (if any) Funded by Takeda

neurosciences,clinical neurology